AMG 222

Drug Profile

AMG 222

Alternative Names: ALS 2-0426

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alantos Pharmaceuticals
  • Developer Amgen
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 17 Jul 2007 Alantos has been acquired by Amgen
  • 07 Jun 2007 Phase-II clinical trials in Type-2 diabetes mellitus in USA (PO)
  • 26 Oct 2006 ALS 20426 has been licensed to Servier worldwide (except for the US)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top